These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11404031)

  • 1. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect.
    Dalmora ME; Dalmora SL; Oliveira AG
    Int J Pharm; 2001 Jul; 222(1):45-55. PubMed ID: 11404031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in hexadecyltrimethylammonium bromide based microemulsion.
    Dalmora ME; Oliveira AG
    Int J Pharm; 1999 Jul; 184(2):157-64. PubMed ID: 10387944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of piroxicam beta-cyclodextrin complex on experimental inflammation.
    Amado CA; Taniguchi SF; Sudo LS; Kimura E; Oga S
    Gen Pharmacol; 1995 Jul; 26(4):809-13. PubMed ID: 7635256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic profile of piroxicam beta-cyclodextrin, in rat plasma and lymph.
    Kimura E; Bersani-Amado CA; Sudo LS; Santos SR; Oga S
    Gen Pharmacol; 1997 May; 28(5):695-8. PubMed ID: 9184804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of piroxicam: hydroxypropyl-beta-cyclodextrin complexation on the in vitro permeation and skin retention of piroxicam.
    Doliwa A; Santoyo S; Ygartua P
    Skin Pharmacol Appl Skin Physiol; 2001; 14(2):97-107. PubMed ID: 11316968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.
    Deroubaix X; Stockis A; Allemon AM; Lebacq E; Acerbi D; Ventura P
    Eur J Clin Pharmacol; 1995; 47(6):531-6. PubMed ID: 7768257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supermolecular inclusion of piroxicam with beta-cyclodextrin: pharmacokinetic properties in man.
    Woodcock BG; Acerbi D; Merz PG; Rietbrock S; Rietbrock N
    Eur J Rheumatol Inflamm; 1993; 12(4):12-28. PubMed ID: 7805700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal lontophoresis and skin retention of piroxicam from gels containing piroxicam: hydroxypropyl-beta-cyclodextrin complexes.
    Doliwa A; Santoyo S; Ygartua P
    Drug Dev Ind Pharm; 2001 Sep; 27(8):751-8. PubMed ID: 11699826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microemulsion-Based Topical Hydrogels of Tenoxicam for Treatment of Arthritis.
    Goindi S; Narula M; Kalra A
    AAPS PharmSciTech; 2016 Jun; 17(3):597-606. PubMed ID: 26285672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piroxicam-β-cyclodextrin: a GI safer piroxicam.
    Scarpignato C
    Curr Med Chem; 2013; 20(19):2415-37. PubMed ID: 23394552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application.
    Gupta SK; Bansal P; Bhardwaj RK; Jaiswal J; Velpandian T
    Skin Pharmacol Appl Skin Physiol; 2002; 15(2):105-11. PubMed ID: 11867967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piroxicam encapsulated in liposomes: characterization and in vivo evaluation of topical anti-inflammatory effect.
    Canto GS; Dalmora SL; Oliveira AG
    Drug Dev Ind Pharm; 1999 Dec; 25(12):1235-9. PubMed ID: 10612018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro release studies of piroxicam from oil-in-water creams and hydroalcoholic gel topical formulations.
    Rafiee-Tehrani M; Mehramizi A
    Drug Dev Ind Pharm; 2000 Apr; 26(4):409-14. PubMed ID: 10769782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative population pharmacokinetic-pharmacodynamic analysis for piroxicam-beta-cyclodextrin and piroxicam.
    Wang D; Miller R; Zheng J; Hu C
    J Clin Pharmacol; 2000 Nov; 40(11):1257-66. PubMed ID: 11075311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin.
    Bannwart B; Bertin P; Péhourcq F; Schaeverbeke T; Gillet P; Lefrançois G; Trèves R; Dehais J; Netter P; Gaucher A
    Int J Clin Pharmacol Ther; 2001 Jan; 39(1):33-6. PubMed ID: 11204935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supermolecular inclusion of piroxicam with beta-cyclodextrin: a review of its pharmacological properties in laboratory animals.
    Lister RE; Acerbi D; Cadel S
    Eur J Rheumatol Inflamm; 1993; 12(4):6-11. PubMed ID: 7805705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergetic skin targeting effect of hydroxypropyl-β-cyclodextrin combined with microemulsion for ketoconazole.
    Che J; Wu Z; Shao W; Guo P; Lin Y; Pan W; Zeng W; Zhang G; Wu C; Xu Y
    Eur J Pharm Biopharm; 2015 Jun; 93():136-48. PubMed ID: 25845772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro percutaneous absorption of piroxicam through synthetic membranes and abdominal rat skin.
    Santoyo S; Arellano A; Ygartua P; Martín C
    Pharm Acta Helv; 1996 Jul; 71(2):141-6. PubMed ID: 8810580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piroxicam-beta-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states.
    Lee CR; Balfour JA
    Drugs; 1994 Dec; 48(6):907-29. PubMed ID: 7533698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation, characterization, and stability studies of piroxicam-loaded microemulsions in topical formulations.
    Abd-Allah FI; Dawaba HM; Ahmed AM
    Drug Discov Ther; 2010 Aug; 4(4):267-75. PubMed ID: 22491209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.